Similar to IFN-β GA is not effective in reducing the disability in progressive MS [168,169] but, for its long-term efficacy and safety, is the most common first-line therapy registered worldwide for RRMS [170]. The gene discussed is IFNB1; the disease is myeloid sarcoma.